Alkermes, Cephalon deal

ALKS partnered with CEPH to commercialize Vivitrex injectable extended-release naltrexone to treat alcohol dependence in the U.S. Vivitrex is under FDA review with a Sept. 30 PDUFA date. ALKS will re...